EmStop Device to Catch Debris During Aortic Valve Replacement for Aortic Stenosis
Tests the EmStop device for catching debris during transcatheter aortic valve replacement.
Key facts
- Who runs it
- EmStop Inc
- Where
- Ann Arbor, Asheville, Clearwater, New Orleans, Rapid City, San Antonio, and Thousand Oaks, United StatesSee the 7 sites
- Trial code
- Registry title
- CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
- Status
- Recruiting
- People taking part
- 663 people, planned
- Started
- 12 May 2026
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EmStop Embolic Protection System
- Boston Scientific Sentinel
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 22 or older with aortic valve disease who are planned for an elective TAVR procedure with a self-expanding valve, through the groin artery.
- Age
- 22 years or older
- Sex
- All sexes can join.
- Disease stage
- Aortic valve disease needing an elective transfemoral self-expanding TAVR on a native or an earlier replacement (valve-in-valve) aortic valve. Heart pumping strength (ejection fraction) of 30% or more.
- Earlier treatment
- No stroke or mini-stroke (TIA) in the prior 6 months. No other heart surgery or left heart procedure planned during TAVR or in the 30 days before it.
- Biomarker or test result
- A heart ultrasound and a CT scan of the arteries within 6 months before the procedure must show that the study device fits. Ascending aorta length of 8 cm (3.1 in) or more and femoral and iliac artery diameter of 8.0 mm or more are asked for one device.
Main reasons for not taking part
- Needs a balloon-expandable valve for the procedure
- Stroke or TIA in the prior 6 months, or a past stroke with lasting major disability
- Ejection fraction under 30%, cardiogenic shock, or heart attack within 30 days
- Kidney failure (eGFR under 30 mL/min) or severe liver failure (Child-Pugh class C)
- Pregnant or breastfeeding, or taking part in another drug or device study
The registry criteria, word for word
Show all 35 criteriaShow less
Who cannot take part
- Documented history of stroke or transient ischemic attack (TIA) within the prior 6 months, or any prior stroke with a permanent major disability or deficit (National Institute of Health Stroke Scale [NIHSS] >1 at baseline)
- Planned to undergo any other open cardiac surgical or left heart interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 30 days prior to the TAVR procedure. The need for a postoperative pacemaker implant after TAVR is not exclusionary
- History of intolerance, allergic reaction, or contraindication to any of the study medications, including heparin, aspirin, clopidogrel, or a sensitivity to contrast media or anesthesia that cannot be adequately pre-treated
- Currently participating in another drug or device clinical study
- Acute myocardial infarction (MI) within 30 days of the planned index procedure
- History of bleeding diathesis or major coagulopathy
- Hepatic failure (Child-Pugh class C)
- Known allergy to any materials used in the EmStop system (e.g., nitinol)
- Left ventricular ejection fraction <30%, cardiogenic shock, or hypotension requiring inotropes or mechanical circulatory support, within 3 months prior to index procedure
- Renal failure, defined as estimated glomerular filtration rate (eGFR) <30 mL/min
- Active endocarditis or ongoing systemic infection, defined as fever (>38°C) and/or WBC >15,000 IU
- Known or suspected to be pregnant, or is lactating; women of child bearing age must have a negative serum or urine pregnancy test within 48 hours prior to the index study procedure
- Requires use of a balloon-expandable transcatheter aortic valve for the index procedure
- Hypercoagulable state that cannot be corrected by additional periprocedural heparin
- Undergoing therapeutic thrombolysis
- Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
- Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Other criteria
- Clinical Inclusion Criteria
- Age ≥ 22 years at the time of consent
- Meets FDA-approved indications for elective transfemoral self-expanding transcatheter aortic valve replacement (TAVR) procedure on a native or non-native (valve-in-valve) aortic valve. Note: Due to Neurologist availability and importance of capturing the neurological assessments, procedures must be performed Monday-Thursday
- Left ventricular ejection fraction ≥ 30% as confirmed by echocardiogram
- Willing and able to provide written informed consent and written HIPAA authorization prior to initiation of study procedures
- Willing and able to comply with the protocol-specified procedures and assessments; Imaging Inclusion Criteria
- Echocardiogram including left ventricular ejection fraction ≥ 30% within 6 months (180 days) prior to the index procedure and prior to randomization to confirm adequate cardiac function
- Subjects must undergo a computed tomography angiography (CTA) scan within 6 months (180 days) prior to the index procedure and prior to randomization to confirm anatomic compatibility with the study device and the control device. Subjects must meet the following anatomical inclusion criteria:; EmStop Angiographic (CTA) Inclusion Criteria 1. Subject anatomy is compatible with correct device positioning with:
- Ascending aorta length ≥8 cm
- Femoral and iliac artery minimal lumen diameter of ≥ 8.0 mm
- Ascending aorta/aortic arch diameter is ≥25 or ≤40 mm
- Ascending aorta or aortic arch exhibits ≤ Grade 1 atheromatous disease and limited wall calcification; Sentinel Angiographic (CTA) Inclusion Criteria
- Subject anatomy, excluding bovine arch anatomy, is compatible with correct device positioning with:
- Artery diameter is 9-15 mm for the brachiocephalic artery and 6.5-10 mm in the left common carotid artery
- Arterial stenosis <70% in either the left common carotid artery or the brachiocephalic artery
- Brachiocephalic or left carotid artery without significant stenosis, ectasia, dissection, or aneurysm at the aortic ostium or within 3 cm of the aortic ostium
- Adequate blood flow to the right upper extremity
- Access vessels without excessive tortuosity
Where in United States
- University of Michigan Health | Michigan MedicineAnn Arbor, United StatesContact: Paul M Grossman, MD (principal investigator)Taking people
- Mission HealthAsheville, United StatesContact: Michaeal Chenier, MD (principal investigator)Taking people
- Morton Plant Hospital | BayCare HealthClearwater, United StatesContact: Joshua Rovin, MD (principal investigator)Taking people
- Ochsner Medical CenterNew Orleans, United StatesContact: James S Jenkins, MD (principal investigator)Taking people
- Monument Health Heart and Vascular InstituteRapid City, United StatesContact: Joseph Tuma, MD (principal investigator)Taking people
- Methodist Research InstituteSan Antonio, United StatesContact: Jorge Alvarez, MD (principal investigator)Taking people
- Los Robles Regional Medical CenterThousand Oaks, United StatesContact: Saibal Kar, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
The objective of this study is to demonstrate safety and efficacy of the EmStop Embolic Protection System when used as indicated to capture and remove thrombus/debris during self-expanding transcatheter aortic valve replacement (TAVR) procedures.
The 2 groups in the trial
- EmStop SystemTreatment being tested
Treatment: EmStop Embolic Protection System
- Boston Scientific Sentinel deviceExisting treatment, for comparison
Treatment: Boston Scientific Sentinel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Controlled Arterial Protection to Ultimately Remove Embolic Material
- Plain-language title
- EmStop Device to Catch Debris During Aortic Valve Replacement for Aortic StenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 August 2026